Author

M. Rousculp

h-index 8 View on Semantic Scholar

We have 3 of 39 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 Period

Background/Objectives: The Novavax COVID-19 vaccine (Nuvaxovid™) was authorized in France in December 2021, assisting in ending the global pandemic and providing an alternative to other COVID-19 vaccines. Understanding Nuvaxovid recipients’ profile is essential for guiding vaccination decision-making and maintaining pr...

S. H. Read, Lucie Kutikova, G. Gusto et al. · Vaccines · 0 citations

Review Open access Sep 2026

Real-world evaluation of 2023–2024 XBB.1.5 mRNA and protein-based COVID-19 vaccine reactogenicity from the randomized BEEHIVE trial

ABSTRACT The objective of this analysis was to assess reactogenicity profile differences between a protein- and mRNA-based COVID-19 vaccine in participants who had previously received ≥2 doses of an mRNA-based vaccine in a real-world, double-blinded, randomized, controlled trial. In the BEEHIVE/NCT06065176 trial (Clini...

Sarang K. Yoon, Andrew L. Phillips, Hong-Wei Zhao et al. · Human Vaccines & Immunothera... · 0 citations

Open access Jul 2026

Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial).

The results suggest that both protein-based and mRNA vaccines are well-tolerated and significantly reduce the risk of symptomatic SARS-CoV-2 infections.

Sarang K. Yoon, Andrew L. Phillips, S. Battan-Wraith et al. · Vaccine · 1 citation